Detailed analysis of the SURMOUNT-1 phase 3 tirzepatide trial — 72-week efficacy data, ~20.9% mean weight reduction, safety profile, and 2026 research implications.
Deep dive on GLP-1 receptor agonism — binding affinities, signaling cascades, GIP/GLP-1 dual agonism, and triple-agonist research from 2024–2026 literature.
Peptide Sciences ceased operations in March 2026. What happened, why it changed the research peptide market, and how to evaluate suppliers after the shutdown.
How HPLC works for peptide purity verification, what a real Certificate of Analysis must show, and how third-party HPLC + MS testing protects your research integrity.
Definitive 2026 guide to research peptides — quality verification, 9 research categories, FDA compliance, and supplier selection after the industry shake-up.
Side-by-side comparison of 5 research peptides — tirzepatide, retatrutide, cagrilintide, AOD-9604, 5-Amino-1MQ — with verified 2024–2026 trial data.
15-point vendor evaluation framework for research peptide suppliers — third-party HPLC, COA, compliance posture, and red flags after the 2025–2026 enforcement wave.
10-point research-grade retatrutide verification checklist — third-party HPLC, MS identity, COA review, and red-flag detection after the 2025–2026 quality crisis.
Step-by-step starter guide for new peptide researchers — fundamentals, vendor selection, first-order workflow, and how to design your first protocol.
Printable one-page reference for reading a research peptide Certificate of Analysis — HPLC, MS, Karl Fischer, endotoxin, batch traceability, red flags.